| 論文編號: |
|
| 第一作者所在部門: |
|
| 中文論文題目: |
Structure- Based Discovery and Optimization of Furo[3,2-c]pyridin-4(5H)-one Derivatives as Potent and Second Bromodomain (BD2)-Selective Bromo and Extra Terminal Domain (BET) Inhibitors |
| 英文論文題目: |
Structure- Based Discovery and Optimization of Furo[3,2-c]pyridin-4(5H)-one Derivatives as Potent and Second Bromodomain (BD2)-Selective Bromo and Extra Terminal Domain (BET) Inhibitors |
| 作者: |
Junhua Li#, Cheng Zhang#, Hongrui Xu, Chao Wang, Ruibo Dong, Hui Shen, Xiaoxi Zhuang, Xiaoshan Chen, Qiu Li, Jibu Lu, Maofeng Zhang, Xishan Wu, Kerry M. Loomes, Yulai Zhou, Yan Zhang, Jinsong Liu, and Yong Xu* |
| 論文出處: |
|
| 刊物名稱: |
Journal of Medicinal Chemistry |
| 年: |
2022 |
| 卷: |
65 |
| 期: |
7 |
| 頁: |
5760-5799 |
| 聯係作者: |
Yong Xu |
| 收錄類別: |
|
| 影響因子: |
8.039 |
| 摘要: |
Pan-bromodomain and extra terminal (Pan-BET) inhibitors show profound efficacy but exhibit pharmacology-driven toxicities in clinical trials. The development of domain-selective BET inhibitors to separate efficacy and toxicity is urgently needed. Herein, we report a series of furo[3,2-c]pyridin-4(5H)-one derivatives as novel BD2-selective BET inhibitors. The representative compound8l(XY153) potently bound to BRD4 BD2 with an half-maximum inhibitory concentration (IC50) value of 0.79 nM and displayed 354-fold selectivity over BRD4 BD1. Besides,8lexhibited 6-fold BRD4 BD2 domain selectivity over other BET BD2 domains. Compound8ldisplayed potent antiproliferative activity against multiple tumor cell lines, especially MV4-11 (IC50= 0.55 nM), while showing weak cytotoxicity against the normal lung fibroblast cell line. It highlights the safety profile of this series of BD2 inhibitors.8lalso demonstrated good metabolic stability in vitro. These data indicate that8lmay serve as a new and valuable lead compound for the development of potential therapeutics against acute myeloid leukemia (AML). |
| 英文摘要: |
|
| 外單位作者單位: |
|
| 備注: |
|
